Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jun;78(6):508-12.
doi: 10.1136/adc.78.6.508.

Neurological outcome of methylmalonic acidaemia

Affiliations

Neurological outcome of methylmalonic acidaemia

P Nicolaides et al. Arch Dis Child. 1998 Jun.

Abstract

Objective: To assess the long term outcome of patients with methylmalonic acidaemia in a cross sectional study.

Patients: All 35 patients with methylmalonic acidaemia seen at Great Ormond Street Hospital for Children in London, UK between 1970 and 1996 were studied. They were divided into cobalamin responsive (n = 6) and non-responsive (n = 29), and early and late onset groups.

Results: There was a significant difference between cobalamin responsive and non-responsive groups in severity, survival, and incidence of neurological sequelae. Cobalamin responsive patients had mild disease, irrespective of age at presentation, their neurological complications were less severe, and they are all alive. The cobalamin non-responsive group comprised 19 early and nine late onset patients. The early onset patients had more severe disease at presentation and 14 have died; all late onset patients are alive. There was no significant difference in abnormal neurological signs, although early onset patients had a significantly reduced full scale intelligence quotient and poor cognitive outcome. In both groups, abnormal neurological signs continue to increase with age.

Conclusions: Cobalamin responsive patients have a better long term outcome. The outcome in the non-responsive patients, particularly the early onset group, remains poor and alternative treatments should therefore be considered early in this group.

PubMed Disclaimer

References

    1. Arch Dis Child. 1967 Oct;42(225):492-504 - PubMed
    1. Brain Res. 1996 May 20;721(1-2):120-5 - PubMed
    1. N Engl J Med. 1983 Apr 14;308(15):857-61 - PubMed
    1. AJNR Am J Neuroradiol. 1983 Jul-Aug;4(4):955-7 - PubMed
    1. Ann Neurol. 1986 Sep;20(3):364-6 - PubMed

MeSH terms